Celularity Inc. (CELU) Stock Score, Valuation & Financial Research
Celularity Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 17/100.
Quick answer for CELU
Celularity Inc. currently has a Wall Street Score of 17/100. The stored market price is $1.37. Its financial score is 4/100. Its valuation score is 0/100. The latest WSS change is +0.6 points. These figures are a research snapshot, not a buy or sell recommendation.
What Celularity Inc. does
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2
CELU financial snapshot
- Wall Street Score:
- 17/100
- Current price:
- $1.37
- Market capitalization:
- $39.7M
- Revenue:
- $26.6M
- Net income:
- $-91.7M
- Free cash flow:
- $-13.3M
- Cash:
- $6.2M
- Total debt:
- $40.9M
- EPS:
- -3.69
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 13/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-13.3M, showing cash burn in the current stored period.
- The balance sheet shows $6.2M of cash versus $40.9M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.6 points: CELU increased 0.6 points because Asset improved by 4.7 points.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-14.
How to research CELU
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.